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ChemokineAcute lung injury is an inﬂammatory condition for which treatment is mainly supportive because effective
therapies have not been developed. Cannabidiol, a non-psychotropic cannabinoid component of marijuana
(Cannabis sativa), has potent immunosuppressive and anti-inﬂammatory properties. Therefore, we investi-
gated the possible anti-inﬂammatory effect of cannabidiol in a murine model of acute lung injury. Analysis
of total inﬂammatory cells and differential in bronchoalveolar lavage ﬂuid was used to characterize leukocyte
migration into the lungs; myeloperoxidase activity of lung tissue and albumin concentration in the bronch-
oalveolar lavage ﬂuid were analyzed by colorimetric assays; cytokine/chemokine production in the bronch-
oalveolar lavage ﬂuid was also analyzed by Cytometric Bead Arrays and Enzyme-Linked Immunosorbent
Assay (ELISA). A single dose of cannabidiol (20 mg/kg) administered prior to the induction of LPS (lipopoly-
saccharide)-induced acute lung injury decreases leukocyte (speciﬁcally neutrophil) migration into the lungs,
albumin concentration in the bronchoalveolar lavage ﬂuid, myeloperoxidase activity in the lung tissue, and
production of pro-inﬂammatory cytokines (TNF and IL-6) and chemokines (MCP-1 and MIP-2) 1, 2, and
4 days after the induction of LPS-induced acute lung injury. Additionally, adenosine A2A receptor is involved
in the anti-inﬂammatory effects of cannabidiol on LPS-induced acute lung injury because ZM241385 (4-(2-
[7-Amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol) (a highly selective antago-
nist of adenosine A2A receptor) abrogated all of the anti-inﬂammatory effects of cannabidiol previously de-
scribed. Thus, we show that cannabidiol has anti-inﬂammatory effects in a murine model of acute lung
injury and that this effect is most likely associated with an increase in the extracellular adenosine offer and
signaling through adenosine A2A receptor.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
The discovery of cannabinoid receptors (CB1 and CB2-cannabinoid
receptors) and their major ligands N-arachidonoylethanolamide (anan-
damide) and 2-arachidonoylglicerol led to the characterization of the
endocannabinoid system more than two decades ago (Devane et al.,
1992; Matsuda et al., 1990; Mechoulam et al., 1995; Munro et al.,
1993). The endocannabinoid systemhas become a topic of great interest+55 11 3091 7829.
evier OA license.in pharmacology due to its remarkable distribution in mammals and its
capacity to play a modulating role in diverse physiological functions in-
cluding immunomodulation and inﬂammation (Di Marzo and
Petrocellis, 2006).
Cannabidiol is a major non-psychotropic cannabinoid component
of marijuana (Cannabis sativa) (Zuardi, 2008). Cannabidiol has been
shown to have potent immunosuppressive and anti-inﬂammatory
properties in several rodent models of inﬂammation (Mechoulam et
al., 2002). A single dose of cannabidiol has been shown to suppress
serum TNF production induced by lipopolysaccharide (LPS) in mice
(Carrier et al., 2006) and has been found to be beneﬁcial in murine
collagen-induced arthritis by inhibiting IFN-γ production and T cell
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orally administered was effective in reducing inﬂammation in a
model of acute carrageenan-induced paw inﬂammation (Costa et al.,
2004a), and that the anti-nociceptive effect was mediated by the
transient receptor potential vanilloid (TRPV1) receptor (Costa et al.,
2004b). Moreover, it was shown that cannabidiol reduced not only
acute but also chronic inﬂammatory responses (Costa et al., 2007).
Acute lung injury and itsmost severe form, acute respiratory distress
syndrome, is a lung disease with acute onset that is characterized by bi-
lateral pulmonary inﬁltrates (Grommes and Soehnlein, 2011). Acute
lung injury is characterized by alveolar-capillary injury and inﬂamma-
tion with neutrophil accumulation as well as by the release of pro-
inﬂammatory cytokines (Tsushima et al., 2009). Acute lung injury can
result in persistent respiratory failure and prolonged dependence on
mechanical ventilation, increased susceptibility tomulti-organ dysfunc-
tion and mortality (Rubenfeld et al., 2005). Despite numerous innova-
tions in intensive care medicine, the mortality related to these
conditions is reported to be around 40% (Rubenfeld et al., 2005; Ware
and Matthay, 2000).
Cannabidiol has a broad spectrum of pharmacological actions
(Mechoulam et al., 2002; Zuardi, 2008), including inhibition of an
equilibrative nucleoside transporter, which in turn leads to the in-
crease of extracellular adenosine (Carrier et al., 2006). Increase in
the adenosine signaling is thought to be the major mechanism by
which cannabidiol decreases inﬂammation (Izzo et al., 2009). Adeno-
sine signaling through adenosine A2 receptors (A2A and A2B) has been
reported to play an important role in the resolution of LPS-induced
acute lung injury (Eckle et al., 2009). Thus, we hypothesized that,
by increasing extracellular levels of adenosine, cannabidiol would de-
crease inﬂammation in a murine model of acute lung injury. There-
fore, our goal was to investigate the potential anti-inﬂammatory
effect of cannabidiol in a murine model of acute lung injury induced
by intra-nasal instillation of LPS.
2. Materials and methods
2.1. Animals
Male C57BL/6 mice from our own colony, weighing 20–25 g and
approximately 60 days old, were used. Animals were housed in tem-
perature controlled (22–24 °C) and artiﬁcially lit rooms on a 12 h
light/12 h dark cycle (lights on at 7:00 a.m.) with free access to ro-
dent chow and water. Sterilized, residue-free wood shavings were
used as animal bedding. The experiments were performed in a differ-
ent room that was maintained at the same temperature as the animal
colony fromwhich the animals were transferred. Animals were main-
tained in their home cages for 7 days before the beginning of the ex-
periments. Animals were housed and used in accordance with the
guidelines of the Committee on Care and Use of Laboratory Animal
Resources of the School of Veterinary Medicine, University of São
Paulo (Protocol # 2002/2010).
2.2. Drugs
Cannabidiol (THC-Pharm, Frankfurt, Germany and STI-Pharm,
Brentwood, UK) was prepared in ethanol:tween 20:saline (1:1:18)
and administered at 0.3, 1.0, 10, 20, 30, 40, and 80 mg/kg intra-
peritoneally (i.p.) (0.1 mL/10 g weight). Control animals received a
similar volume of vehicle alone. Sixty minutes after treatment, acute
lung injury was induced as described below. ZM241385 (4-(2-[7-
Amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]
ethyl)phenol) (Tocris Bioscience, Missouri, USA), an antagonist of the
adenosine A2A receptor, was prepared in ethanol:tween 20:saline
(1:1:18) and was administered i.p. at 5 mg/kg 30 min prior to canna-
bidiol treatment; this diluent was used in control and cannabidiol-
treated mice.2.3. Acute lung injury
Mice were anesthetized with ketamine and xylazine injected i.p.
(100 and 10 mg/kg, respectively) before intranasal instillation of
LPS. Escherichia coli LPS (O55:B5 L2880, Sigma-Aldrich, St. Louis,
USA) at a concentration of 100 μg/mL, or as a control, sterile 0.9% sa-
line was instilled at 1 μL/g of mouse body weight. At 1, 2, 4, and 7 days
after instillation, mice were anesthetized and killed by exsanguina-
tion through the inferior vena cava.2.4. Leukocyte trafﬁcking
2.4.1. Bronchoalveolar lavage ﬂuid
Brieﬂy, mice were killed at 1, 2, 4, and 7 days after LPS instillation
by exsanguination through the inferior vena cava after ketamine
(100 mg/kg) and xylazine (10 mg/kg) i.p. anesthesia, and bronchoal-
veolar lavage ﬂuid was collected. Lungs were lavaged with 1.5 mL of
phosphate-buffered saline (PBS) solution through a cannula inserted
into the trachea. Bronchoalveolar lavage ﬂuid recovery was always
around 1 mL. It was collected and centrifuged at 250×g for 5 min
and the remaining cell pellet was resuspended in 1 mL of PBS. Total
leukocyte counts were performed after adding 10 μL of crystal violet
to 90 μL of the cell suspension. Neubauer chambers were used for
cell counting under a light microscope. Differential counts were per-
formed on cytocentrifuge preparations (FANEM, São Paulo, Brazil)
stained with Rosenfeld's dye using standard morphological criteria.2.4.2. Blood
White blood cells were counted with an automatic cell counter
(ABC Vet®, São Paulo, Brazil).2.4.3. Bone marrow
The total number of bone marrow cells was quantiﬁed from fem-
oral marrow lavage. Both epiphyses of collected femurs were cut off,
and the bone marrow was ﬂushed with 5 mL ice-cold PBS. The cell
suspension was centrifuged at 250×g for 5 min, and the remaining
cell pellet was resuspended for total leukocyte counts in Neubauer
chambers.2.5. Myeloperoxidase activity
The lungs were perfused via the pulmonary artery with 10 mL of
PBS. Samples were prepared according to Goldblum et al. (1985).
Brieﬂy, a lung fraction was homogenized with 1 mL of PBS containing
0.5% of hexadecyl-trimethylammonium bromide and 5 mM EDTA, pH
6.0. Samples were homogenized and centrifuged at 30,000×g for
10 min. Aliquots of lung homogenates (10 μL) were then incubated
for 5 min with a solution containing H2O2 (0.1%) and ortho-
dianisidine. The reaction was stopped by the addition of 1% NaNO3.
The absorbance was determined at 450 nm using a microplate reader
(Bio-Tek Instruments®, Winooski, VT, USA). To normalize pulmonary
myeloperoxidase activity between groups, the absorbance was stan-
dardized to lung weight.2.6. Cytokine and chemokine analysis
A BDTM cytometric bead array (CBA) mouse inﬂammation kit (BD
Biosciences, San Jose, USA) was used to measure IL-6, IL-10, MCP-1,
IFN-γ, TNF, and IL-12p70, and an ELISA kit (R&D Systems, Minneapo-
lis, USA) was used to measure MIP-2 in the bronchoalveolar lavage
ﬂuid. The assays were performed according to the manufacturer's
instructions.
Fig. 1. Dose–response curve for the effects of cannabidiol in a murine model of acute lung injury. (A) Total leukocyte counts and (B) TNF concentration in the bronchoalveolar lavage
ﬂuid. Data are presented as the mean±S.E.M., n=4–5 mice/group. *Pb0.05 when compared with the vehicle+LPS group; **Pb0.001 when compared with the vehicle+LPS
group; and ***Pb0.0001 when compared with the vehicle+LPS group. Statistics were calculated by one-way ANOVA followed by a Tukey–Kramer test (parametric data).
Fig. 2. Effects of cannabidiol on total leukocyte count in the bronchoalveolar lavage
ﬂuid 1, 2, 4, and 7 days after the induction of LPS-induced acute lung injury. Data are
presented as the mean±S.E.M., n=5–9 mice/group. **Pb0.001 when compared with
the vehicle+LPS group; ***Pb0.0001 when compared with the vehicle+LPS group.
Statistics were calculated by one-way ANOVA followed by a Tukey–Kramer test (para-
metric data).
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Bronchoalveolar lavage ﬂuid aliquots were placed in a 96-well ELISA
plate (10 μL/well), and 250 μL of Bradford reagent (Sigma-Aldrich, St.
Louis, USA) was added to each well; after a 30 min incubation, the ab-
sorbance was measured at 595 nm. A standard curve using bovine
serum albumin (BSA, Sigma-Aldrich, St. Louis, USA) was obtained plot-
ting the net absorbance vs. the protein concentration (1.5–0.1 mg/mL)
to determine protein concentration in the samples.
2.8. Statistical analysis
GraphPad Prism 5.0 (GraphPad Software, Inc.) was used for statis-
tical analysis. Parametric data were analyzed by one-way ANOVA fol-
lowed by a Tukey–Kramer test for multiple comparisons. A Kruskal–
Wallis test followed by a Dunn's test for multiple comparisons was
used to analyze non-parametric data. Myeloperoxidase activity and
bronchoalveolar lavage ﬂuid protein concentration data were ana-
lyzed by normalizing to percent of control (vehicle+Sal) and then
comparing vehicle+LPS and cannabidiol+LPS groups using a
Mann–Whitney U test. In all experiments, P≤0.05 was considered
signiﬁcant. Data are presented as the mean±S.E.M.
3. Results
3.1. Cannabidiol has dose-dependent anti-inﬂammatory effects on acute
lung injury
We ﬁrst performed a dose–response curve for cannabidiol using leu-
kocyte migration into the lungs and TNF production in the bronchoal-
veolar lavage ﬂuid as readouts 1 day after the induction of LPS-
induced acute lung injury. Importantly, LPS instillation was effective in
inducing lung inﬂammation as can be observed by the number of leuko-
cytes (F (8,33)=5.9; Pb0.0001) (Fig. 1A) and the concentration of TNF
(F (8,33)=7.8; Pb0.0001) (Fig. 1B) observed in the bronchoalveolar la-
vage ﬂuid 1 day after the induction of acute lung injury. We observed
that cannabidiol at 20 (Pb0.05), 30 (Pb0.05), and 80 (Pb0.01) mg/kg
decreased leukocyte migration into the lungs (F (8,33)=5.9)
(Fig. 1A). We also observed that cannabidiol at 10 (Pb0.05), 20
(Pb0.01), 30 (Pb0.05), and 80 (Pb0.0001) mg/kg decreased TNF pro-
duction in the bronchoalveolar lavage ﬂuid (F (8,33)=7.8) (Fig. 1B).
3.2. Cannabidiol treatment persistently decreases leukocyte migration
into the lungs
Based on the previous resultswe selected the dose of 20 mg/kg of can-
nabidiol for the next experiments. We selected this dose because it wasthe minimal dose that effectively decreased both leukocyte migration
into the lungs and TNF production in the bronchoalveolar lavage ﬂuid.
We then investigated the effects of cannabidiol (20 mg/kg) on leukocyte
migration into the lungs 1, 2, 4, and 7 days after the induction of acute
lung injury.We observed that cannabidiol treatment decreased leukocyte
counts 1 (F (2,15)=27.4; Pb0.0001), 2 (F (2,16)=38.6; Pb0.0001), and
4 (F (2,17)=17.3; Pb0.001) days after the induction of lung inﬂamma-
tion (Fig. 2). Lung inﬂammation was resolved by 7 days after the induc-
tion of inﬂammation, and further changes due to cannabidiol were
therefore not observed (Fig. 2).
We analyzed leukocyte distribution in the blood and bone marrow;
howeverwe did not observe any signiﬁcant differences between groups
at any time point analyzedwith the exception of an increase in the bone
marrow counts in the vehicle+LPS and the cannabidiol+LPS groups
when compared with the vehicle+Sal group 7 days after the induction
of inﬂammation (F (2,17)=4.9; Pb0.05) (Table 1).
We also performed differential analysis of leukocytes in the bronch-
oalveolar lavage ﬂuid, andwe found that cannabidiol decreased neutro-
phil, lymphocyte, and macrophage migration into the lungs 1, 2, and
4 days after the induction of ALI (Table 2). Seven days after the induc-
tion of acute lung injury, we found minimal neutrophilic inﬂammation
in the lungs of control-treated mice (vehicle+LPS), and we observed
that this was ablated by cannabidiol treatment (F (2,17)=5.519;
Pb0.05) (Table 2).
Table 1
Effects of cannabidiol on total leukocyte distribution in the bone marrow and blood.
Groups Bone marrow (cells×106) Blood (cells×103/mm3)
1 day 2 days 4 days 7 days 1 day 2 days 4 days 7 days
Vehicle+Sal 3.3±0.3 2.8±0.5 4.7±0.3 3.3±0.3 6.5±0.8 7.7±1.0 5.2±0.4 4.9±0.3
Vehicle+LPS 2.9±0.2 3.3±0.3 4.7±0.4 4.5±0.3a 7.9±0.8 10.8±1.3 6.2±0.4 6.1±0.4
Cannabidiol+LPS 3.0±0.2 2.8±0.4 4.0±0.3 4.4±0.2a 7.3±1.2 9.3±1.5 5.4±0.3 6.1±0.5
Data are expressed as the mean±S.E.M. Statistics were calculated by one-way ANOVA followed by Tukey–Kramer or Kruskal–Wallis followed by Dunn's multiple comparison tests
(for parametric and non-parametric data, respectively).
a Pb0.05 when compared with the vehicle+Sal group.
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Because of the important role neutrophils play in the acute lung
injury, we analyzed myeloperoxidase activity in the lungs of mice 1,
2, 4, and 7 days after the induction of inﬂammation. We observed
that cannabidiol treatment signiﬁcantly decreased myeloperoxidase
activity 2 (U=3.0; Pb0.01) and 4 days (U=7.5; Pb0.05) after the in-
duction of inﬂammation. By 7 days after the induction of acute lung
injury, we did not observe any changes, most likely because the
lung inﬂammation had already resolved (Fig. 3).
3.4. Cannabidiol decreases production of pro-inﬂammatory cytokines
and chemokines in the bronchoalveolar lavage ﬂuid
We next investigated inﬂammatory cytokines/chemokines in the
bronchoalveolar lavage ﬂuid 1, 2, 4, and 7 days after the induction
of acute lung injury. One day after the induction of inﬂammation,
we observed that cannabidiol decreased TNF concentration
(F (2,11)=15.7; Pb0.01) (Fig. 4A); no statistically signiﬁcant differ-
ences were observed for IL-12p70, IL-10 (data not shown), IL-6, and
MCP-1 (Fig. 4) between the groups, with the exception that there
was a trend towards a decrease in MIP-2 production (P=0.06)
(Fig. 4). Two days after the induction of acute lung injury, we ob-
served that cannabidiol decreased TNF (F (2,12)=5.5; Pb0.05), IL-6
(F (2,12)=8.9; Pb0.01) (Fig. 4B), MCP-1 (F (2,12)=14.3;
Pb0.0001) (Fig. 4C), and MIP-2 (KW=10.6; Pb0.05) (Fig. 4D) con-
centrations; the other cytokines analyzed (IL-12p70 and IL-10)
remained unchanged at this time point. Four and 7 days following
the induction of acute lung injury, no differences were observed in
any of the cytokines/chemokines analyzed (data not shown). The
levels of IFN-γ were below the limit of quantiﬁcation in the bronch-
oalveolar lavage ﬂuid samples.
3.5. Cannabidiol decreases vascular permeability
Finally, we investigated vascular permeability indirectly by mea-
suring protein in the bronchoalveolar lavage ﬂuid. We observed that
cannabidiol decreased the protein concentration in the bronchoalveo-
lar lavage ﬂuid 1 (U=5.5; P=0.05) and 2 (U=7.0; P=0.05) daysTable 2
Effects of cannabidiol on differential cell analysis in the bronchoalveolar lavage ﬂuid.
Groups Neutrophil (cells×105) Macrophage/m
1 day 2 days 4 days 7 days 1 day 2
Vehicle+Sal .03±.01 0.2±0.1 .04±.01 .03±.01 0.4±.04 0.
Vehicle+LPS 1.1±0.2 3.2±0.5 0.1±.01 0.2±0.1 2.8±0.4 3.
Cannabidiol+LPS 0.4±.03b 1.4±0.3b .05±.01a 0.1±.01a 1.5±0.2b 2.
Data are expressed as the mean±S.E.M. Statistics were calculated by one-way ANOVA follo
a Pb0.05 when compared with the vehicle+LPS group.
b Pb0.001 when compared with the vehicle+LPS group.
c Pb0.0001 when compared with the vehicle+LPS group.after the induction of acute lung injury (Fig. 5). Four and 7 days
after the induction of acute lung injury, no differences were observed
in protein concentration in the bronchoalveolar lavage ﬂuid.
3.6. Adenosine A2A receptor antagonism attenuates the anti-inﬂammatory
effects of cannabidiol on acute lung injury
Cannabidiol is known to exert its actions through a number of dif-
ferent mechanisms (Zuardi, 2008). For example, it has been reported
that blocking (with ZM241385) or knocking out the adenosine A2A re-
ceptor, abrogated the ability of cannabidiol to decrease the TNF pro-
duction induced by systemic administration of LPS (Carrier et al.,
2006). Therefore, we investigated the role of the adenosine A2A recep-
tor in the anti-inﬂammatory effects of cannabidiol reported here by
using ZM241385, a highly selective adenosine A2A receptor antago-
nist. We observed that ZM241385 treatment abrogated cannabidiol
inhibition of leukocyte migration into the lungs (Fig. 6A) and myelo-
peroxidase activity in the lung tissue (Fig. 6B) 1, 2, and 4 days after
the induction of acute lung injury. Moreover, ZM241385 attenuated
cannabidiol inhibition of inﬂammatory cytokines/chemokines in the
bronchoalveolar lavage ﬂuid (Fig. 6C–F) and vascular permeability
(Fig. 6G) 1 and 2 days after the induction of acute lung injury. As
expected, 7 days after the induction of inﬂammation, no differences
were observed.
4. Discussion
Cannabidiol is a major non-psychoactive cannabinoid component
of marijuana (C. sativa) (Zuardi, 2008) and has been shown to have
potent immunosuppressive and anti-inﬂammatory properties
(Mechoulam et al., 2002). Therefore, we wondered whether cannabi-
diol would be as effective in a murine model of acute lung injury, due
to its potent anti-inﬂammatory property, as it has been reported in
other models of inﬂammation (Mechoulam et al., 2002). We report
here that a single dose of cannabidiol is able to induce a decrease in
several lung inﬂammation parameters, such as leukocyte migration
(neutrophil, macrophages, and lymphocytes), myeloperoxidase activ-
ity, pro-inﬂammatory cytokine/chemokine production, and vascularonocyte (cells×105) Lymphocyte (cells×105)
days 4 days 7 days 1 day 2 days 4 days 7 days
4±0.1 0.5±0.1 0.9±0.2 0.1±.03 0.2±.04 0.1±.01 0.1±.01
8±0.3 1.9±0.2 1.0±0.2 0.7±0.1 1.5±0.2 0.2±.03 0.3±0.1
2±0.5a 1.0±0.2b 0.7±0.1 0.2±.03c 0.4±0.1c 0.1±.02a 0.1±.01
wed by Tukey–Kramer test (parametric data).
Fig. 3. Effects of cannabidiol on myeloperoxidase activity in the lung tissue 1, 2, 4, and
7 days after the induction of LPS-induced acute lung injury. Data are presented as the
mean±S.E.M., n=6–8 mice/group. *Pb0.05 when compared with the vehicle+LPS
group; **Pb0.001 when compared with the vehicle+LPS group. Statistics were calcu-
lated by normalizing the data to percent of the control group (vehicle+Sal); the vehi-
cle+LPS and cannabidiol+LPS groups were then compared using the Mann–Whitney
U test (non-parametric data).
Fig. 5. Effects of cannabidiol on protein (albumin) concentration in the bronchoalveolar
lavage ﬂuid 1, 2, 4, and 7 days after the induction of LPS-induced acute lung injury. Data
are presented as the mean±S.E.M., n=6–7 mice/group. *Pb0.05 when compared with
the vehicle+LPS group. Statistics were calculated by normalizing the data to percent of
the control group (vehicle+Sal); the vehicle+LPS and cannabidiol+LPS groups were
then compared by Mann–Whitney U test (non-parametric data).
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acute lung injury. We also show that signaling through adenosine
A2A receptor is most likely the mechanism mediating the anti-
inﬂammatory effects of cannabidiol in our work.Fig. 4. Effects of cannabidiol on cytokine/chemokine production in the bronchoalveolar lava
(B) IL-6, (C) MCP-1 (CCL2), and (D) MIP-2 (CXCL2). Data are presented as the mean±S.E.M.,
when compared with the vehicle+LPS group; and ***Pb0.0001 when compared with the v
Kramer test (parametric data).Neutrophil inﬂux into the interstitium and the bronchoalveolar space
is considered to play a key role in the progression of acute lung injury
(Grommes and Soehnlein, 2011). We found that cannabidiol (20 mg/
kg) decreases leukocyte migration into the lungs of mice 1, 2, and
4 days after the induction of acute lung injury, as shown by thege ﬂuid 1, 2, 4, and 7 days after the induction of LPS-induced acute lung injury. (A) TNF,
n=4–7 mice/group. *Pb0.05 when compared with the vehicle+LPS group; **Pb0.001
ehicle+LPS group. Statistics were calculated by one-way ANOVA followed by a Tukey–
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neutrophilmigration is greatly decreased and thatmacrophage and lym-
phocyte numbers are also decreased in cannabidiol-treatedmice. Leuko-
cyte migration into the site of inﬂammation is extremely important in
both tissue damage and resolution of tissue injury. Moreover, neutro-
phils are highly specialized for their primary function, which are phago-
cytosis and destruction of microorganisms (Klebanoff, 2005).
Myeloperoxidase analysis is considered a good surrogate for the tissue
neutrophil activity that occurs predominantly under pathological condi-
tions. We show that myeloperoxidase activity is decreased in
cannabidiol-treated mice with ongoing lung inﬂammation 1, 2 and
4 days after the induction of acute lung injury model. This effect may
be important because myeloperoxidase-associated tissue damage will
likely be inhibited, which could also contribute to decrease lung
inﬂammation.
It is noteworthy that neutrophil migration into the lungs is not
sufﬁcient to cause acute lung injury, because neutrophils can migrate
into the lungs without causing injury; therefore, neutrophil activation
is required (Grommes and Soehnlein, 2011). Thus, we also analyzed
the production of pro-inﬂammatory cytokines and chemokines in
the bronchoalveolar lavage ﬂuid of mice with ongoing LPS-induced
acute lung injury. We show that TNF and IL-6 are decreased in
cannabidiol-treated mice 1 and 2 days after the induction of acute
lung injury. These results are extremely important because both cyto-
kines are essential to the establishment of inﬂammation and to
phagocyte activation. Consistent with our results, it has been reported
that the inhibition of the TNF-converting enzyme reduces LPS-
induced acute lung injury in rats (Shimizu et al., 2009). Additionally,
we show that cannabidiol decreases MIP-2 (CXCL2) 1 and 2 days after
the induction of acute lung injury and decreases MCP-1 (CCL2) 2 days
after the induction of acute lung injury. These results may explain the
dynamics of leukocyte migration into the lungs. MIP-2 promotes neu-
trophil migration and degranulation (Kobayashi, 2008); therefore, it
is reasonable to suggest that cannabidiol, by reducing MIP-2 production
in the bronchoalveolar lavage ﬂuid, reduces the neutrophil count and
also decreases myeloperoxidase activity during ongoing lung inﬂamma-
tion. Moreover, supporting our observations, it has been shown that
blocking (Zarbock et al., 2008) or knocking out (Reutershan et al.,
2006) theMIP-2 receptor (CXCR2) leads to the attenuation of neutrophil
migration and inﬂammation in amodel of acute lung injury. MCP-1 con-
centration in the bronchoalveolar lavage ﬂuid may also explain the re-
duced numbers of macrophages and lymphocytes that we observed in
the differential analysis of the bronchoalveolar lavage ﬂuid. Therefore,
these data are extremely important because cannabidiol modiﬁes the
cytokine/chemokine milieu in the lungs of mice submitted to experi-
mental acute lung injury, which seems to be important to the pro-
nounced anti-inﬂammatory effects in cannabidiol-treated mice that
we observed in our work.
Cannabidiol is known to exert its effects in a number of different
ways, as reviewed by Izzo et al. (2009) and Zuardi (2008). Among
them, the inhibition of adenosine uptake and signaling through the
adenosine A2A receptor was shown to be involved in the anti-
inﬂammatory actions of cannabidiol (Carrier et al., 2006). Indeed, aden-
osine signaling has been shown to play an important role in the attenu-
ation of experimentally induced acute lung injury (Ngamsri et al., 2010;
Reutershan et al., 2007; Schingnitz et al., 2010; Wagner et al., 2010).
Therefore, we decided to investigate the involvement of activation of
the adenosineA2A receptors in the anti-inﬂammatory effects of cannabi-
diol using ZM241385, a highly selective antagonist of the adenosine A2A
receptors. Remarkably, ZM241385 treatment abrogated all anti-
inﬂammatory effects of cannabidiol at all time points reported here;
leukocyte migration into the lungs, myeloperoxidase activity, produc-
tion of pro-inﬂammatory cytokines/chemokines, and vascular perme-
ability were all reduced 1, 2, 4, and 7 days after the induction of
inﬂammation. Corroborating with our data, it has been reported that
the activation of adenosine A2A receptor decreases neutrophil migrationinto the lung, cytokine/chemokine production, vascular permeability,
etc., in murine models of acute lung injury (Impellizzeri et al., 2011;
Reutershan et al., 2007). Although ZM241385 is a highly selective aden-
osine A2A receptor antagonist, we cannot conclude that the abrogation
of the anti-inﬂammatory effects of cannabidiol in the LPS-induced
acute lung injury was speciﬁcally mediated by A2A receptor since
ZM241385 also binds to adenosine A2B receptor (Poucher et al., 1995),
especially at the dose we used in our work (5 mg/kg).
It should not be forgotten that the pharmacological proﬁle of can-
nabidiol is complex and other mechanisms besides signaling
through adenosine receptors might be involved. Cannabidiol has
been shown to inhibit fatty acid amide hydrolase (FAAH) and anan-
damide reuptake (Bisogno et al., 2001). This effect could contribute
to the anti-inﬂammatory effect of cannabidiol, since it has been
shown in other model of inﬂammation, such as intestinal inﬂamma-
tion (Capasso et al., 2008). Cannabidiol has also been shown to have
CB2 inverse agonistic property, which could contribute to its docu-
mented anti-inﬂammatory properties (Thomas et al., 2007). Re-
duced activity of 5-lipoxygenase (5-LOX) was also attributed as a
molecular mechanism of cannabidiol (Massi et al., 2008); although
this effect was analyzed in the context of cannabidiol antitumoral ac-
tivity, it might also contribute to cannabidiol anti-inﬂammatory ef-
fect. Recently, in an in vitro model of hypoxic-ischemic brain
damage, it has been shown that cannabidiol decreased pro-
inﬂammatory mediators, such as cyclooxygenase (COX-2) and in-
ducible nitric oxide synthase (iNOS), as well as TNF and IL-6
(Castillo et al., 2010). They also showed that both CB2 and especially
adenosine A2A receptor are involved in these anti-inﬂammatory ef-
fects (Castillo et al., 2010). Finally, some efforts are being made to
improve our understanding of cannabidiol actions at the intracellu-
lar level, and it is noteworthy to describe them here. It was shown
that cannabidiol decreases the production and release of pro-
inﬂammatory cytokines such as IL1-β and IL-6 from LPS-activated
microglial cells and that cannabidiol reduces the activity of NF-κB,
which regulates the expression of pro-inﬂammatory cytokines. Canna-
bidiol also decreased the activation of STAT1 transcription factor, an im-
portant regulator of the IFNβ-dependent pro-inﬂammatory process.
Moreover, it was shown that cannabidiol up-regulates the activation of
the STAT3 transcription factor, a counteracting mechanism inducing
anti-inﬂammatory events.
Finally, it was shown that inhibition of pro-inﬂammatory cyto-
kines induced by cannabidiol is not mediated by the CB1 and CB2 can-
nabinoid receptors (Kozela et al., 2010).
Nevertheless, in our model of LPS-induced acute lung injury, inhibi-
tion of adenosine uptake and signaling through the adenosine A2A re-
ceptor seems to be the most likely mechanism involved in the anti-
inﬂammatory effect observed.
5. Conclusions
We show for the ﬁrst time that a single dose of cannabidiol has anti-
inﬂammatory effects in amurinemodel of LPS-induced acute lung injury.
Additionally,we show that augmentation of adenosine signaling through
the adenosine A2A receptor is themost likely mechanism controlling the
actions of cannabidiol in our work. Currently, we are investigating
whether cannabidiol is able to decrease LPS-induced acute lung injury
when the inﬂammatory process is already installed. Additionally, care
should be takenwhen extrapolating these data to patients; nevertheless,
in the future, cannabidiol may prove useful as a therapeutic tool for the
treatment/attenuation of inﬂammatory lung diseases, such as acute
lung injury and acute respiratory distress syndrome.
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